SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Are Development Times For Pharmaceuticals Increasing Or Decreasing?
4 references·3 citing·27 second hop
Are Development Times For Pharmaceuticals Increasing Or Decreasing? (2006)Are Development Times For Pharmaceuticals…Trends in development and approval times for new therapeutics in the United States (2003)Trends in development and app…The price of innovation: new estimates of drug development costs (2003)The price of innovation: new …Strategic Pricing of New Pharmaceuticals (1998)Strategic Pricing of New Phar…Pharmaceutical Economics and Policy (1998)Pharmaceutical Economics and …Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents (2018)Medicare Spending on Brand-na…The Use of Flexible Manufacturing Capacity in Pharmaceutical Product Introductions* (2009)The Use of Flexible Manufactu…Estimated research and development costs of rotavirus vaccines (2009)Estimated research and develo…Investment under Uncertainty (1994)Competitive Markov Decision Processes (1996)Utilizing customer knowledge in innovation: antecedents and impact of customer involvement on new product performance (2015)An Integrative approach to supply chain disruption risk and resilience management: a literature review (2020)A New Product Growth for Model Consumer Durables (1969)A New Product Growth Model for Consumer Durables (1976)Health Care Financing Review (1980)Parallel imports and the pricing of pharmaceutical products: evidence from the European Union (2004)The Economics of Follow-on Drug Research and Development (2004)The Pharmaceutical Industry (2013)Cost of innovation in the pharmaceutical industry (1991)Stocks, bonds, bills, and inflation yearbook (1993)Risks in new drug development: Approval success rates for investigational drugs (2001)Can the pharmaceutical industry reduce attrition rates? (2004)Clinical development success rates for investigational drugs (2014)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)The cost of biopharmaceutical R&D: is biotech different? (2007)Estimating the Cost of Industry Investment in Drug Research and Development: A Review of Methods and Results (2021)The $2.6 Billion Pill — Methodologic and Policy Considerations (2015)The High Cost of Prescription Drugs in the United States (2016)Health Care Spending in the United States and Other High-Income Countries (2018)Science, pharmacoeconomics and ethics in drug R&D: a sustainable future scenario? (2004)An Empirical Review of Major Legislation Affecting Drug Development: Past Experiences, Effects, and Unintended Consequences (2011)How do patent-based measures inform product commercialization? —The case of the United States pharmaceutical industry (2018)Trends of generic substitution in community pharmacies. (1999)Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration (2007)A competition‐based explanation of collaborative invention within the firm (2013)
this work references cited by second hop

References

  • 2003The price of innovation: new estimates of drug development costs4,312 cited
  • 2003Trends in development and approval times for new therapeutics in the United States260 cited
  • 1998Strategic Pricing of New Pharmaceuticals249 cited
  • 1998Pharmaceutical Economics and Policy136 cited

Cited by

  • 2009Estimated research and development costs of rotavirus vaccines50 cited
  • 2018Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents48 cited
  • 2009The Use of Flexible Manufacturing Capacity in Pharmaceutical Product Introductions*17 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work